ActoGeniX: 20 million euros round


Ghent – The Belgian biopharma start-up ActoGeniX has closed a series A financing round in the volume of a20 million. The transaction was co-led by the two renowned VC investors Life Sciences Partners and GIMV. ActoGeniX has already announced a first closing of this transaction, raising a11.5 million. The company, which was founded in summer 2006, is developing a portfolio of novel therapeutic products addressing major diseases with unmet medical need, including gastrointestinal diseases, auto-immunity, allergy and metabolic diseases. ActoGeniX’ initial focus is on inflammatory bowel diseases and its lead product AG011 has been successfully tested in a clinical trial with Crohn’s disease patients. The company’s technology provides a solution to deliver active biologicals locally in the gastrointestinal tract, leading to a direct effect on target receptors present in the gut.



Leiden – Overshadowed by contamination problems at Crucell N.V.’s vaccine plant in South Korea, pharmaceutical and healthcare giant Johnson & Johnson has continued the purchase of 82.5 % of the Dutch biotechnology vaccine maker...



Leuven – Researchers from Leuven University have demonstrated that German Merck’s monoclonal EGF receptor (EGFR) antagonist cetuximab (Erbitux) offers benefits to patients with metastatic colorectal cancer even when they carry...



Brussels - Healthcare institutions from Europe have launched a new pilotprocess testing multi-stakeholder consultations in early-stage drugdevelopment. The purpose of the project is to reach an agreement about whatconstitutes a...



Leiden/New Brunswick – Johnson & Johnson will acquire all outstanding shares of Dutch Crucell N.V. for approximately EUR1.75 billion in a recommended cash tender offer, according to the companies. J&J said that it expects to...



Leiden/News Brunswick - Johnson & Johnson is set to bag all outstanding shares of Dutch protein and vaccine developer Crucell N.V. Currently Johnson & Johnson, through an affiliate, holds approx. 17.9% of the shares of Crucell...



Rotterdam/Leuven – Cartilage replacement specialist TiGenix N.V. has entered into an agreement with its academic partners KU Leuven and Ghent University, the Dutch company Therosteon and a consortium of investors for the...



Groningen – Researchers from the University of Groningen have identified a new mechanism that enables cancer cells to resist platinum-based chemotherapy. In resistant cancer stem cells of patients with testicular cancer, the team...

Displaying results 71 to 80 out of 304

< Previous 71-80 Next >

© 2007-2015 BIOCOM

Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...

Product of the week



All videos


All Events

Stock list

All quotes


  • MEDIGENE12.51 EUR18.92%
  • CO.DON2.88 EUR9.09%
  • FORMYCON26.77 EUR8.91%


  • 4SC1.16 EUR-7.20%
  • MOLOGEN5.69 EUR-2.07%
  • CYTOS1.43 CHF-1.38%


  • CYTOS1.43 CHF320.6%
  • MEDIGENE12.51 EUR194.4%
  • FORMYCON26.77 EUR60.3%


  • MORPHOSYS60.10 EUR-19.6%
  • BASILEA108.20 CHF-11.5%
  • WILEX3.10 EUR-9.6%


  • SANTHERA96.50 CHF2312.5%
  • FORMYCON26.77 EUR271.8%
  • WILEX3.10 EUR198.1%


  • CYTOS1.43 CHF-52.5%
  • MOLOGEN5.69 EUR-49.4%
  • PAION2.53 EUR-24.0%

No liability assumed, Date: 30.03.2015

Current issue

All issues